IRIS
PASSINO, Claudio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 25.866
EU - Europa 17.689
AS - Asia 4.086
Continente sconosciuto - Info sul continente non disponibili 107
SA - Sud America 102
OC - Oceania 51
AF - Africa 40
Totale 47.941
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 24.471
GB - Regno Unito 6.420
IT - Italia 3.412
UA - Ucraina 2.201
DE - Germania 1.673
SG - Singapore 1.535
DK - Danimarca 1.521
CA - Canada 1.313
CN - Cina 1.040
VN - Vietnam 873
SE - Svezia 667
IE - Irlanda 518
FI - Finlandia 396
FR - Francia 343
PL - Polonia 276
HK - Hong Kong 255
EU - Europa 106
MX - Messico 71
IN - India 69
NL - Olanda 64
PK - Pakistan 64
IR - Iran 56
KR - Corea 52
AU - Australia 42
RO - Romania 34
BR - Brasile 28
JP - Giappone 27
SK - Slovacchia (Repubblica Slovacca) 25
RU - Federazione Russa 23
ES - Italia 22
BD - Bangladesh 19
CH - Svizzera 19
AT - Austria 16
PE - Perù 16
CO - Colombia 15
TR - Turchia 15
EC - Ecuador 14
AR - Argentina 12
BE - Belgio 12
ET - Etiopia 12
ID - Indonesia 12
CZ - Repubblica Ceca 11
SA - Arabia Saudita 11
TW - Taiwan 11
AM - Armenia 10
NZ - Nuova Zelanda 9
PT - Portogallo 8
BO - Bolivia 7
GH - Ghana 6
PH - Filippine 6
CL - Cile 5
KE - Kenya 5
KZ - Kazakistan 4
MY - Malesia 4
TN - Tunisia 4
VE - Venezuela 4
ZA - Sudafrica 4
AZ - Azerbaigian 3
EE - Estonia 3
GT - Guatemala 3
HR - Croazia 3
HU - Ungheria 3
KG - Kirghizistan 3
LU - Lussemburgo 3
SC - Seychelles 3
SM - San Marino 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
EG - Egitto 2
GE - Georgia 2
GR - Grecia 2
IL - Israele 2
LA - Repubblica Popolare Democratica del Laos 2
LT - Lituania 2
LV - Lettonia 2
MG - Madagascar 2
NO - Norvegia 2
NP - Nepal 2
PA - Panama 2
QA - Qatar 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
JM - Giamaica 1
KW - Kuwait 1
MA - Marocco 1
MK - Macedonia 1
MM - Myanmar 1
NG - Nigeria 1
NI - Nicaragua 1
PY - Paraguay 1
Totale 47.941
Salva come PNG Salva come JPEG
Città #
Southend 4.837
Woodbridge 2.672
Chandler 2.319
Ann Arbor 2.295
Houston 2.019
Fairfield 1.626
San Mateo 1.470
Falls Church 1.263
Singapore 1.178
Jacksonville 1.089
Dearborn 1.020
Seattle 998
Cambridge 956
Wilmington 841
Ottawa 839
Ashburn 704
Beijing 602
Pisa 532
Stevenage 512
Boardman 504
Dublin 495
Portsmouth 488
Dong Ket 483
Montréal 403
Lawrence 385
Warsaw 266
Redwood City 174
Santa Clara 172
San Diego 168
Rome 164
Old Bridge 158
Milan 153
Brooklyn 150
London 125
Fremont 110
Florence 89
Helsinki 86
Munich 82
Norwalk 67
Central District 60
Hong Kong 59
Livorno 52
Los Angeles 49
Washington 46
Buti 42
Shenzhen 36
Seoul 35
Serra 33
Lappeenranta 32
Wayne 31
Lucca 30
Nanjing 30
Chiswick 28
Foggia 28
Salisbury 28
Shanghai 27
Assago 26
Bologna 26
Frankfurt am Main 26
Genoa 26
Kansas City 26
Bratislava 25
Padova 25
Naples 24
Augusta 23
Hounslow 23
Wandsworth 23
Turin 21
Hanover 20
Sydney 20
Dallas 19
Provo 19
Toronto 19
Hefei 18
Islamabad 18
Bari 17
Dongguan 17
Fuzhou 17
Pavia 17
Simi Valley 17
Guangzhou 16
Jinan 16
Kish 16
Napoli 16
Palermo 16
Redmond 16
Amsterdam 14
Bucharest 14
Cardiff 14
Glasgow 14
Mexico 14
Perugia 14
West Jordan 14
Berlin 13
Cascina 13
Chicago 13
Kilburn 13
Krefeld 13
Kunming 13
Lachine 13
Totale 33.937
Salva come PNG Salva come JPEG
Nome #
Value in Healthcare and the Role of the Patient Voice 637
Valutazione delle caratteristiche analitiche e dei risultati clinici di un metodo in chemiluminescenza a cattura di microparticelle (CMIA) per il dosaggio della Galectina-3 sulla piattaforma ARCHITECT 570
La neuropatia diabetica 243
E-Health in Tuscany Inner Areas: The PROXIMITY-CARE Approach 242
A cross-correlational analysis between electroencephalographic and end-tidal carbon dioxide signals: Methodological issues in the presence of missing data and real data results 237
Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging 219
The calculation of the cardiac troponin T 99th percentile of the reference population is affected by age, gender, and population selection: A multicenter study in Italy. 213
Grapevine microRNAs in an in vitro model of cell line: new potential insight on their role in the setting of human health. 206
Functional ancient grain bread rich in iron, zinc, flavonoids and alpha lipoic acid attenuates post-ischemic myocardial remodeling in rats 203
[ANMCO/ELAS/SIBioC Consensus document: Recommendations for the use of cardiac biomarkers in heart failure patients] 195
Influence of Type of Surgery on the Occurrence of Parasympathetic Reinnervation After Cardiac Transplantation 188
Comparison between BNP values measured in capillary blood samples with a POCT method and those measured in plasma venous samples with an automated platform 185
Myocardial fibrosis as a key determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy: a contrast-enhanced cardiovascular magnetic study 176
Usefulness of high-sensitive troponin elevation after effort stress to unveil vulnerable myocardium in patients with hart failure 176
Comparison of Brain Natriuretic Peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure 174
Cardioprotection by remote ischemic conditioning: Mechanisms and clinical evidences 173
Influence of preload and afterload on stroke volume response to low-dose dobutamine stress in patients with non-ischemic heart failure: A cardiac MR study 172
Human pathophysiological adaptations to the space environment 170
Markers of fibrosis, inflammation, and remodeling pathways in heart failure 169
Autonomic, functional, skeletal muscle, and cardiac abnormalities are associated with increased ergoreflex sensitivity in mitochondrial disease 169
Valutazione delle caratteristiche analitiche di un nuovo metodo di dosaggio del BNP 168
Peripheral reflex feedbacks in chronic heart failure: Is it time for a direct treatment? 168
Treating chemoreflex in heart failure: modulation or demolition? 166
Tuscany Sangiovese Grape juice imparts cardioprotection by regulating gene expression of Cardioprotective C-Type Natriuretic Peptide. 166
Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis 162
Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly? 162
Marcatori di rimodellamento e fibrosi cardiaca 162
Natriuretic peptides as biomarkers of cardiac endocrine function in heart failure: New challenges and perspectives 162
Prognostic Value of Indeterminable Anaerobic Threshold in Heart Failure. 161
B-type natriuretic peptide secretion following scuba diving 161
Radioimmunoassay for plasma C-type natriuretic peptide determination: a methodological evaluation 160
Accuracy of b-GGT fraction for the diagnosis of non-alcoholic fatty liver disease. 160
Severe heart failure prognosis evaluation for transplant selection in the era of beta-blockers: role of peak oxygen consumption 157
Measurement of the pro-hormone of brain type natriuretic peptide (proBNP): methodological considerations and pathophysiological relevance 156
Natriuretic peptides (NPs): Automated electrochemiluminescent immunoassay for N-terminal pro-BNP compared with IRMAs for ANP and BNP in heart failure patients and healthy individuals. 156
Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure 156
Attivazione adrenergica e deattivazione parasimpatica nello scompenso cardiaco. 155
Clinical relevance of non-cardiac determinants of natriuretic peptide levels. 155
Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay of the N-terminal fragment of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. 154
Renal function and peak exercise oxygen consumption in chronic heart failure with reduced left ventricular ejection fraction 154
Response to letters regarding article, "Myocardial fibrosis as a key determinant of left ventricular remodeling in idiopathic dilated cardiomyopathy: a contrast-enhanced cardiovascular magnetic study" 154
Prognostic value of combined use of B-ype natriuretic peptides and interleukine-6 in predicting cardiac mortalità in end-stage renal disease patients 153
Clinical implications of a recent adjustment to the high-sensitivity cardiac troponin T assay: some results. 153
Myocardial damage in a mitochondrial myopathy patient with increased ergoreceptor sensitivity and sympatho-vagal imbalance 153
Usefulness of High-Sensitive Troponin Elevation After Effort Stress to Unveil Vulnerable Myocardium in Patients With Heart Failure 153
Influence of gender on circulating cardiac natriuretic hormones in patients with heart failure. 152
Haematological modifications after acute exposure to high altitude: possible implications for detection of recombinant erythropoietin misuse. 152
These abstracts have been selected for moderated presentations on SCREEN A. Please refer to the the PROGRAM and the infos on the screen for more details about schedule, moderators and presenters. 152
Influence of central apneas and chemoreflex activation on pulmonary artery pressure in chronic heart failure 151
Cardiac production of C-type natriuretic peptide in heart failure. 150
A simple method for measuring baroreflex sensitivity holds prognostic value in heart failure 150
Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy 149
Bioinformatics analysis of the gene profile of coronary endothelial cells treated with Grapevine microRNAs: an in vitro study 149
Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches 149
Analytical performance and clinical results of a fully automated MEIA system for brain natriuretic peptide assay: comparison with a point of care testing method 149
C-type natriuretic peptide and heart failure 148
Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation 148
Cheyne-Stokes Respiration, Chemoreflex, and Ticagrelor-Related Dyspnea 148
N-terminal fragment of B-type natriuretic peptide predicts coexisting subclinical heart and vessel disease 148
Can we measure how hot the plaque is? Not yet, but…. 147
Cocaine assumption and transient myocardial edema in asymptomatic cocaine heavy-users 147
Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice 146
Demonstrable Cardiac Reinnervation After Human Heart Transplantation by Carotid Baroreflex Modulation of RR Interval 145
Influence of ScaI and Natriuretic Peptide (NP) Clearance Receptor Polymorphisms of the NP System on NP Concentration in Chronic Heart Failure. 145
Different substrates of non-sustained ventricular tachycardia in post-infarction patients with and without left ventricular dilatation. 145
Exercise intolerance in chronic heart failure: mechanisms and therapies. Part I. 145
The combined use of neutrophil gelatinase-associated lipocalin and brain natriuretic peptide improves risk stratification in pediatric cardiac surgery 145
Prognostic value of alveolar volume in systolic heart failure: a prospective observational study 145
Myocardial signal intensity decay after gadolinium injection: a fast and effective method for the diagnosis of cardiac amyloidosis 145
Hyperthyroidism is associated with lengthening of ventricular repolarization. 144
b-Gamma-glutamyltransferase activity in human vulnerable carotid plaques. 144
Predicting readmissions after hospitalization for heart failure: Medical reasoning vs calculators 144
Evaluation of analytical performance of a new high-sensitivity immunoassay for cardiac troponin i 144
N-terminal proB-type natriuretic peptide (NT-proBNP) is superior to BNP for the detection of eraly/mild forms of heart failure 143
Update sui biomarcatori nello scompenso cardiaco. 143
Comparison of the diagnostic accuracy of BNP and NT-proBNP in acute and chronic heart failure. Reply Letter 142
Right heart overload contributes to cardiac natriuretic hormone elevation in patients with heart failure. 142
Changes in chemoreflex characteristics following acetazolamide administration in patients with chronic heart failure and Cheyne Stokes respiration 142
Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism 142
N-terminal prob-type natriuretic peptide is a marker of vascular remodelling and subclinical atherosclerosis in asymptomatic hypertensives 142
Cerebral vasoreactivity in Andeans and headache at sea level. 141
Glycosylated haemoglobin is associated with neurohormonal activation and poor outcome in chronic heart failure patients with mild left ventricular systolic dysfunction 141
Exercise tolerance can explain the obesity paradox in patients with systolic heart failure: Data from the MECKI Score Research Group 141
State of the art of aldosterone immunoassays. A multicenter collaborative study on the behalf of the Cardiovascular Biomarkers Study Group of the Italian Section of European Society of Ligand Assay (ELAS) and Società Italiana di Biochimica Clinica (SIBIOC). 140
New and emerging biomarkers of heart failure 139
Natriuretic peptide testing in primary care patients. 139
Cardiac biomarker testing in the clinical laboratory: Where do we stand? General overview of the methodology with special emphasis on natriuretic peptides 139
Accuracy of b-GGT fraction for the diagnosis of non-alcoholic fatty liverdisease. 138
When chronic heart failure intersects chronic obstructive pulmonary disease: impact on long-term prognosis 138
The metabolic exercise test data combined with Cardiac and Kidney Indexes (MECKI) score and prognosis in heart failure. A validation study 138
Clinical relevance of time course of BNP levels in neonates with congenital heart diseases 138
Comparison of the Diagnostic Accuracy of Brain Natriuretic Peptide (BNP) and the N-Terminal Part of the Propeptide of BNP Immunoassays in Chronic and Acute Heart Failure: A Systematic Review 137
N-terminal fragment of brain natriuretic peptide predicts vascular health and subclinical atherosclerosis: results from MEHLP study 137
Cardiovascular risk factors and gamma-glutamyltransferase fractions in healthy individuals. 137
Evaluation of analytical performance of a novel immunoenzymometric assay for cTnI. 137
Gamma-glutamyltransferase as a cardiovascular risk factor. 136
Prognostic complexity of heart failure and network analysis: the holistic risk stratification 136
Cheyne-Stokes respiration is associated with neurohormonal activation in patients with heart failure 136
Prognostic value of plasma renin activity in heart failure patients with chronic kidney disease. 136
Neuro-hormonal activation predicts ventilatory response to exercise and functional capacity in patients with heart failure. 135
Totale 16.565
Salva come PNG Salva come JPEG
Categoria #
all - tutte 278.358
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 278.358
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.227 0 0 0 0 933 730 833 233 609 122 152 615
2020/202110.274 719 1.145 522 924 636 1.457 917 604 630 623 744 1.353
2021/20226.927 477 1.282 379 663 153 119 764 1.269 561 670 114 476
2022/20235.337 402 312 276 790 779 826 53 432 917 106 244 200
2023/20243.247 292 112 528 227 210 337 303 190 191 167 168 522
2024/20252.829 192 234 1.198 489 716 0 0 0 0 0 0 0
Totale 48.546